LSV Asset Management
ALXN

LSV Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

LSV Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,710,802
Closed -$314M – 934
2021
Q2 		$314M Sell
1,710,802
-888,580
-34% -$153M 0.53% 48
2021
Q1 		$397M Sell
2,599,382
-760,704
-23% -$118M 0.68% 32
2020
Q4 		$525M Sell
3,360,086
-182,812
-5% -$23.5M 0.95% 16
2020
Q3 		$405M Buy
3,542,898
+43,464
+1% +$4.69M 0.83% 24
2020
Q2 		$393M Buy
3,499,434
+2,650,007
+312% +$281M 0.81% 26
2020
Q1 		$76.3M Buy
849,427
+178,677
+27% +$17.5M 0.18% 143
2019
Q4 		$72.5M Buy
670,750
+661,950
+7,522% +$70.8M 0.11% 211
2019
Q3 		$861K Buy
+8,800
New +$992K ﹤0.01% 759

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

LSV Asset Management's ALXN Position: Q3 2021 in Review

LSV Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,710,802 shares — an estimated $314M sold.

LSV Asset Management first reported a position in ALXN in Q3 2019 and held it in 8 quarters. The position peaked at $525M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • LSV Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • LSV Asset Management sold 1,710,802 Alexion Pharmaceuticals shares in Q3 2021, an estimated $314M.
  • LSV Asset Management first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 8 quarters.
  • LSV Asset Management's Alexion Pharmaceuticals position peaked at $525M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on LSV Asset Management's 13F filing for Q3 2021, filed 4 Nov 2021.